MGMT Promoter Deep Sequencing for Single-Base Methylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting methylation in the promoter of the O-6-methylguanine-DNA methyltransferase (MGMT) gene, such as methylation-specific PCR (MSP), provide only binary or quantitative overall calls, lacking single-base methylation quantification, which affects the accuracy of predicting patient response to treatments like alkylating agents and radiotherapy for glioblastoma.
Innovation Solution
Utilizing ultra-deep next-generation sequencing (NGS) after bisulfite treatment to analyze the MGMT promoter, allowing for precise quantification of methylation levels at single-base resolution, including coverage of at least 10^3, 10^4, 10^5, or 10^6 reads, to predict treatment response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If methylation-specific PCR (MSP) is used to detect MGMT promoter methylation, then the detection can be performed with simple methodology, but the measurement precision is insufficient as it provides only binary or quantitative overall calls without single-base resolution
Solution Approach 1:
The patent segments the MGMT promoter region into individual CpG sites for separate analysis. Instead of providing a single overall methylation call, the method quantifies methylation status at each individual CpG position (e.g., CpG1, CpG2, CpG3, etc.), enabling single-base resolution measurement. This segmentation transforms the measurement from a bulk average to position-specific quantification, directly resolving the precision limitation of MSP.
Solution Approach 2:
The patent replaces the mechanical/chemical amplification-based detection system (PCR) with a sequencing-based detection system. Instead of relying on PCR amplification and gel electrophoresis or qPCR fluorescence detection, the method uses next-generation sequencing to directly read and count methylated versus unmethylated alleles at each CpG position. This substitution enables precise digital quantification of methylation levels.
2Measurement precision
If ultra-deep NGS is performed to achieve single-nucleotide level methylation assessment, then the measurement precision is improved, but the productivity is reduced due to the time-consuming nature of deep sequencing
Solution Approach 1:
The patent performs preliminary actions by conducting bisulfite treatment and target amplification before sequencing. The bisulfite treatment converts unmethylated cytosines to uracils while leaving methylated cytosines unchanged, creating distinct sequence patterns that can be easily distinguished during sequencing. This preliminary chemical modification simplifies the subsequent sequencing analysis and enables efficient methylation calling from the sequence data.
Solution Approach 2:
The patent changes the sequencing depth parameter to achieve ultra-deep coverage (e.g., 1000x, 10,000x, or higher). By increasing the number of reads covering each CpG position, the method achieves precise quantification of low-frequency methylated alleles. This parameter change enables accurate detection of heterogeneous methylation patterns that would be invisible at lower sequencing depths.
3Measurement precision
If comprehensive deep-sequencing coverage is applied to the MGMT promoter, then the measurement precision of methylation status is improved, but the loss of time increases due to extensive sequencing required
Solution Approach 1:
The patent extracts and sequences only the specific MGMT promoter region containing the CpG islands of interest, rather than performing whole-genome or exome sequencing. By using targeted amplification with primers specific to the MGMT promoter flanking regions, the method enriches for the target sequence, enabling comprehensive deep-sequencing coverage of the promoter with minimal sequencing effort. This extraction approach reduces time and cost while maintaining high measurement precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Ultra-deep NGS provides accurate, single-nucleotide level methylation assessment, outperforming MSP in predicting patient survival and treatment response, particularly when combined with clinical variables like patient age, enhancing predictive accuracy.
Implementation Method 1
performing deep-sequencing of the O-6-methylguanine-DNA methyltransferase (MGMT) promoter in a DNA sample after the DNA sample has been treated with a reagent that modifies unmethylated cytosine
Data Source
AI summary
Disclosed are methods and systems for detecting methylation of the promoter of O-6-methylguanine-DNA methyltransferase gene (MGMT). In particular, the methods and systems may be utilized to detect methylation in the MGMT promoter in a DNA sample from a glioblastoma and optionally in order to predict whether a subject having the glioblastoma will respond to treatment with an alkylating agent. The methods and systems typically include a step of deep-sequencing the DNA sample after the DNA sample has been treated with a reagent that converts unmethylated cytosine to uracil such as a bisulfite reagent.